EyePoint Q2 FY26 net loss widens to $94.47 million; revenue drops to $507,000 - EYPT News | RalliesEyePoint Q2 FY26 net loss widens to $94.47 million; revenue drops to $507,000
E
EYPT• Pipeline milestones ahead
- LUGANO Phase 3 wet AMD topline data expected in August 2026, with LUCIA slated for Q4 2026.
- COMO and CAPRI Phase 3 DME trials fully enrolled, with topline data expected in Q4 2027.
Q2 results widen loss as revenue declines
- EyePoint posted Q2 net loss of USD 94.5 million, or USD 1.09 per share, widening from a loss of USD 59.4 million, or USD 0.85 per share.
- Revenue fell to USD 0.5 million from USD 5.3 million, due to recognition of remaining deferred revenue tied to a 2023 YUTIQ license deal.
- Operating expenses climbed to USD 97.9 million from USD 67.6 million, on higher DURAVYU Phase 3 trial spending and manufacturing scale-up.
- Cash and investments totaled USD 180 million at June 30, down from USD 223 million at March 31; runway forecast into Q4 2027.
